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Abstract
Aim: The management of acute Charcot neuroarthropathy relies on off-loading which
is costly and time-consuming. Published studies have used monitoring techniques
with unknown diagnostic precision to detect remission. We performed a systematic
review of techniques for monitoring response to offloading in acute Charcot
neuroarthropathy.
Materials and Methods: We included studies of off-loading which evaluated or
described monitoring techniques in acute Charcot neuroarthropathy. PubMed,
EMBASE, CINAHL and Cochrane databases were searched (January1993-July 2018).
We extracted data from papers including study design, setting, population, monitor-
ing techniques and treatment outcomes. We also extracted information on the cost,
clinical applicability, sensitivity and specificity, safety and participant acceptability of
the monitoring techniques.
Results: We screened 1205 titles, 140 abstracts and 45 full-texts, and included
29 studies. All studies were of low quality and at high risk of bias. In seven studies,
the primary aim was to evaluate monitoring techniques: three evaluated magnetic
resonance imaging, two thermography monitoring, one three-phase bone scanning
and one Doppler spectrum analysis. The remaining 22 observational studies reported
treatment outcomes and described the monitoring techniques used to assess the
Charcot neuroarthropathy. Heterogeneity prevented the pooling of data. Very few
studies included data on cost, clinical applicability, sensitivity and specificity, safety
and patient acceptability of the monitoring techniques used.
Conclusion: Multiple techniques have been used to evaluate remission in acute Char-
cot neuroathropathy but uncertainty remains about their effectiveness. We recom-
mend further research into the influences of different monitoring techniques on
treatment outcomes.
K E YWORD S
Charcot neuroarthropathy, monitoring, off-loading, remission, systematic review
Received: 24 February 2020 Revised: 17 March 2020 Accepted: 6 April 2020
DOI: 10.1002/dmrr.3328
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2020 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd.
Diabetes Metab Res Rev. 2020;e3328. wileyonlinelibrary.com/journal/dmrr 1 of 25
https://doi.org/10.1002/dmrr.3328
1 | INTRODUCTION
Charcot neuroarthropathy (CN) is a complication of peripheral neu-
ropathy associated with diabetes which affects the lower limb. It may
be precipitated by minor trauma or other inflammatory insult which
the patient does not notice due to insensitivity to pain. When, the
patient does not rest the foot, an exaggerated inflammatory response
occurs.1 The symptoms include redness, warmth and swelling in the
foot and/or leg. It can cause fractures and dislocations within the foot,
which may progress to deformity and ulceration.
The treatment aims to stop the inflammatory process, relieve any
pain and maintain foot structure.2 Treatment for CN is “off-loading”
the application of a non-removable plaster or fibreglass cast or boot;
this rests and immobilizes the foot and redistributes the weight and
pressure from the foot to the leg.3 Off-loading is continued until
remission when there are no longer clinical signs of inflammation, and
X-rays are stable with signs of healing.2
Globally, evidence suggests significant variation in treatment times.
In the United Kingdom, observational studies report treatment times of
9 to 12 months before remission is achieved4-6 whilst data from the
United States7-10 and other European centres report treatment times of
only 4–6 months.11-16 Several factors could contribute to global varia-
tion, include participant characteristics, different techniques for moni-
toring, different protocols for the same monitoring techniques,
variations in approach to off-loading and study design variability.5
The current evidence base for the treatment of CN is poor. It is
principally based on small retrospective cohort and observational stud-
ies of patients attending multidisciplinary foot clinics. Evidence to sup-
port the effectiveness of techniques to monitor CN is lacking, and
current practice is primarily based on expert opinion.2 Skin temperature
is used because CN involves inflammation of the soft tissue and bone.17
Skin temperature is however, a proxy measure of inflammation mea-
sured on the dorsum of the foot over the site of injury, which may not
reflect the degree of inflammation within the affected deeper tissues,
bones and/or joints. X-rays show damage to the foot skeleton rather
than disease activity and are a measure of foot deformity. Despite these
limitations, serial temperature measurements and X-rays remain the
most widely used monitoring technique in CN.
Improvements in monitoring CN could reduce treatment times.
Lack of evidence to support clinicians in the choice of the type of
monitoring and decision thresholds for remission may account for var-
iability in treatment times. To the best of our knowledge, there are no
systematic reviews focused on monitoring techniques to identify
remission in CN.
Therefore, this systematic review aims to identify the effective-
ness of published techniques for monitoring remission in the manage-
ment of acute CN in patients living with diabetes. The objectives are:
1. To identify the techniques used in the monitoring of CN.
2. To identify the sensitivity and specificity of different techniques
used to monitor CN.
3. To identify the financial implications to healthcare providers and
the NHS and the clinical feasibility of identified techniques.
4. To identify the safety considerations, and participant acceptability
of identified techniques.
5. To identify whether different techniques used for monitoring influ-
ence the outcomes of CN.
2 | METHODS
This systematic review adheres to the preferred reporting items for
systematic reviews and meta-analyses (PRISMA) checklist.18 The
protocol was prospectively registered in PROSPERO http://www.
crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD420180
93340(CRD42018093340).19
2.1 | Inclusion and exclusion criteria
The inclusion criteria for study design were purposefully wide, based
on prior knowledge of research studies on CN. We included random-
ized controlled trials, preference-controlled trials, and observational
studies with or without control group(s). We excluded abstracts, sys-
tematic reviews and meta-analyses, studies on surgical and pharmaco-
logical management of CN, expert opinion, observations of single case
studies and laboratory studies.
We included studies on off-loading which evaluated or reported
monitoring techniques in adults with diabetes with a diagnosis of
acute CN managed in any setting, including hospital, primary care or
community. The control condition included other techniques used to
monitor CN or the same technique used differently, for example dif-
ferent protocols for thermographic monitoring.
2.2 | Search strategy
We completed searches in PubMed, Embase, CINAHL, the Cochrane
Central Register of Controlled Trials and ClinicalTrials.gov. The
searches were restricted to English language, from 1993 to June 2018
and adapted for each database. See Appendix 1 for an example search
strategy for PubMed. We used search terms for diabetes, Charcot,
neuroarthropathy and osteoarthropathy. We also checked the refer-
ence lists of relevant published systematic reviews.
We downloaded all papers identified into EndNote and removed
duplicates. Screening was conducted independently by two reviewers
(C.G. and K.G.) in all three phases: title, abstract and full-text screen-
ing. Reasons for exclusion were recorded during abstract and full text
screening. Inter-rater agreement was calculated by the number of
papers on which the two reviewers agreed in terms of inclusion and
exclusion, divided by the total number of double screened papers.
Discrepancies were resolved by consensus (C.G. and K.G.). All records
deemed eligible following this consensus process were included for
full text assessment or data extraction.
We extracted information on participant characteristics including
type of diabetes, duration and HbA1c. We also extracted information
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on sensitivity and specificity of the techniques, protocol for applica-
tion of the technique, costs and feasibility, safety and participant con-
siderations. Finally, we extracted methods of off-loading and clinical
outcomes such as time to healing and relapse rates.
The first author (C.G.) extracted data from all included papers.
The completed data extraction sheets were independently validated
by a second reviewer (K.G.) against the papers. Given the wide range
of study designs included, data synthesis was narrative.
Records idenfied through 
database searching  
n = 1705 
PubMed n = 781  
CINHAL n = 67 
EMBASE n = 857 
Addional records idenfied 
through other sources n = 0  
Cochrane n = 0 
Clinical Trial. gov n = 0 
Records aer duplicates removed  
(n = 1205) 
Records screened 
(n = 1205) 
Records excluded  
(n = 1065) 
Full-text arcles assessed 
for eligibility  
(n = 45) 
Studies included in 
narrave synthesis  
(n = 29) 
Full-texts excluded, with reasons 
(n =16) 
Descripve case report= 1 
Other aspects of care= 4 
Prevalence/incidence data= 6 
Alternave outcomes= 5 
Abstracts assessed for 
eligibility  
(n = 140) 
Abstracts excluded, with reasons 
(n = 95) 
Review/leer/teaching= 62 
Conference abstract= 10 
Single case report= 7 
Other aspects of care= 12 
Prevalence data= 4 
F IGURE 1 Preferred reporting items for systematic reviews and meta-analyses diagram
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3 | RESULTS
3.1 | Search results
After removal of duplicates, we identified 1205 papers (Figure 1) and
excluded 1065 during title screening. During abstract screening we
excluded 95/140 papers, most exclusions concerned reviews, papers
describing other aspects of care and conference abstracts. Inter-rater
agreement during title screening was 94.1% (1134/1205), and 81.4%
(114/140) during abstract screening 87% (39/45). Forty-five full text
papers were screened; most common exclusion reasons were that
studies described other aspects of care, and outcomes or were epide-
miological reports.
We included 29 papers (Table 1). We used the Scottish Intercolle-
giate Guidelines Network criteria for assigning level of evidence.
Three papers were case control and one a cohort study, that is, level
2 studies. The remaining 25 were level 3, non-analytic case series. Ten
studies were prospective and the remaining 19 retrospective reviews
of medical records. All included studies were of low or very low
quality.
3.2 | Study and participant characteristics
Eight studies were conducted in the United States, four studies in
Germany, and two in Denmark, Switzerland, Italy, and Brazil (Table 2).
In total, 1132 participants were included across all studies with 1239
episodes of CN. Mean sample size was 39 (±27 range 13-115). The
studies collected data for between 4 months and 23 years.
The mean age of participants was reported in 20 studies and
ranged from 52 to 62.5 years old. Participants' sex was reported in
26 studies: 56% (614/1095) who experienced an episode of acute CN
in these studies were male (range 4-68). Twenty-three studies clearly
reported the type of diabetes. 67.7% (598/896) of participants with
acute CN had a diagnosis of type 2 diabetes (range 5-84). The mean
duration of all types of diabetes ranged from 13.0 to 24.5 years. Any
data reported on severity and anatomical location of the CN are
reported in Table 2.
We divided the studies into two groups. In the first group, the
evaluation of monitoring techniques was the study's primary aim, so
likely to report data to address the first four objectives on the efficacy
and acceptability of the techniques.11,21-25,38 In the second group, the
study's primary aim was to report outcomes of CN but they may also
describe monitoring techniques used, thus providing data to answer
our fifth objective on whether monitoring techniques influence
outcomes.6-10,12-16,26-37
3.3 | Techniques used in the monitoring of CN
Table 3 summarizes the protocols used to monitor CN. Of the seven
studies included in the first group, three evaluated magnetic resonance
imaging (MRI) for monitoring CN.11,21,24 The first study compared
dynamic MRI, with gadolinium contrast medium, every 3 months with
foot skin temperature measured with a handheld infrared temperature
scanner and midfoot and ankle circumference in 40 participants with
CN.11 The authors concluded that contrast medium uptake rate
obtained with dynamic-MRI represents a reliable technique for
predicting remission in acute CN. Intra- and inter-observer agreement
for assessment of contrast medium uptake was high: correlation
(k) = 0.96. The authors reported a 90% agreement between clinical find-
ings and MRI. The mean healing time at clinical examination was
6.8 ± 2.3 months and 8.3 ± 2.9 at MRI. In 23% of participants, the clini-
cal signs of disease stabilization were found 3 to 6 months prior to the
stabilization observed on MRI. The second study retrospectively
reviewed the notes and images of 45 episodes of CN over 23 years.
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14 of 25 GOODAY ET AL.
They reviewed sequential follow-up MRIs to assess the change in
oedema equivalent signal change during treatment for CN with a walk-
ing cast. The number of follow-up MRIs per episode of CN ranged from
1 to 6. They found decreasing oedema-equivalent signal change in 69%
(66/95) of follow-up MRIs but reported a combination of physiologic
and pathologic fluctuations in oedema equivalent signal change in the
remainder of the MRIs.21 The third study compared bone marrow
oedema on MRI at baseline and after 4 months, and correlated this to
symptoms of CN in 13 participants. There was a statistically significant
decrease in bone oedema over 4 months, with a statistically significant
correlation between pain and soft tissue oedema and the bone marrow
oedema over the same timescale.24
Two studies evaluated infrared thermometry to identify disease
remission.23,38 The first study described in detail the protocol for mea-
suring temperature using the Exergen Model DT 1001. They controlled
for ambient room temperature, allowed a 15 minute acclimatization
period, and measured seven sites on the foot, compared with the con-
tralateral limb as the physiologic control, at monthly intervals.38 Casting
was discontinued based on reduction or absence of clinical signs of
inflammation, radiologic signs of healing and when the temperature dif-
ference between feet had stabilized with a cut-off point of less than
4F (2.2C) difference. The authors report that the choice of the cut-off
figure was based on clinical experience The second study referenced
the protocol described by Armstrong and Lavery38 for measuring tem-
perature but used the Minitemp, Raytec23 to monitor temperature.
Casting was discontinued when the temperature difference between
feet was recorded as less than 2C.
One study evaluated Doppler spectrum analysis as a novel diag-
nostic tool for planning treatment.25 The study compared the Doppler
spectra of the first metatarsal arteries in both feet using a 10 MHz lin-
ear ultrasound probe (ATL HDI3000 or HDI5000; ATL, Bothel,
Washington). The Doppler spectra in the unaffected limb were tri-
phasic, compared to the affected limb which showed monophasic for-
ward flow. The Doppler spectra analysis was repeated every 2 weeks
in the affected limb until it returned to normal. At this point, partici-
pants either started weight-bearing or underwent surgical reconstruc-
tion of the ankle joint. The authors concluded that Doppler spectra
analysis of the foot may be used as a guide to begin weight bearing.
They reported a discrepancy between the two monitoring techniques:
only four out of 15 patients had X-rays which showed healing when
the foot was healed according to the Doppler Spectra analysis.
In the final study, a subset of eight participants from a larger
study received three monthly three-phase quantitative bone scans of
both feet for a maximum of 12 months. They compared the ratio of
isotope uptake between feet, between the affected foot and the tibia
and compared isotope uptakes to the clinical indicators of inflamma-
tion. There was strong correlation between temperature difference
and the ratio of isotope uptake in the affected vs unaffected foot, the
perfusion of the affected foot in the dynamic phase and the isotope
uptake in the delayed phase of the bone scans.22 The study also
reported on the change in temperature difference between the
affected and unaffected foot from baseline 3.3C, at 6 months 1.3C,






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































GOODAY ET AL. 21 of 25
In the remaining 22 studies, the primary aim was to evaluate the
outcomes of CN but they described the monitoring techniques used
(Table 3). The most frequent monitoring techniques used was serial X-
ray in 16/22 of studies, objective temperature measurement with a
handheld infrared monitoring device in 11/22 and MRI with or with-
out contrast media in 7/22 of studies. Protocols for the same tech-
nique were not standardized across studies. For example, in studies
that used infra-red skin temperature measurement to monitor CN,
some studies used a cut of <1C and others <2C to identify remis-
sion. Some studies relied on a combination of different monitoring
techniques: 5/22 described two techniques, 4/22 described three
techniques and one study used four techniques to monitor CN.
Four studies used advanced radiological methods for diagnostic
and/or monitoring: F-FDG PET/CT scanning,16 bone scintigram,13
bone biopsies30 and isotope bone scans.12 Other monitoring tech-
niques included objective and subjective measures of inflammation by
palpating foot temperature, and assessing the presence of swell-
ing.7,8,12,15,35 Another study assessed progression of foot deformity
by visual examination, palpation and comparison of serial photo-
graphs.26 Objective, serial measures of water displacement and grad-
ing of midfoot stability were used to monitor CN in another study.9
3.3.1 | Sensitivity and specificity of different
techniques used to monitor CN
Six out of seven studies which evaluated monitoring techniques did
not report the sensitivity or specificity. Zampa et al11 reported a high
intra and inter observer agreement for the assessment of contrast
uptake but did not report the sensitivity of the technique. They
reported that the monitoring techniques evaluated could be used as a
guide to identify remission, withdraw immobilization, and begin
weight bearing. None of the 22 studies reporting the outcomes of CN
reported the specificity or sensitivity of the monitor techniques used
to measure when the foot was in remission. Some studies relied on
subjective monitoring techniques such as palpation or visual inspec-
tion of inflammation to assess for remission in CN.
3.3.2 | Financial implications to healthcare
providers and clinical feasibility of different
techniques
No studies reported the cost of the monitoring used in terms of capi-
tal cost to purchase equipment.
3.3.3 | Safety considerations, and participant
acceptability of different techniques
Ten out of 29 studies used MRI as a monitoring tool for identifying
remission of acute CN. Of these, four reported using contrast during
the MRI in all or some images at the radiologist's discretion.11,16,24,26
A further four studies used advanced methods of radiological
imaging which require the use of contrast media.12,13,16,22 Only one
of these 14 studies which used contrast specifically reported on the
incidence of adverse events from the administration of the contrast,
reporting no adverse events. Another study reported using bone
biopsy as a diagnostic aid to confirm CN, but this was not used in
monitoring.30 They did not report any safety considerations that may
be relevant to this technique. X-rays are associated with exposure to
ionizing radiation, but their potential risk was not discussed in any
studies. No safety considerations were reported for objective temper-
ature measurement with a handheld infrared monitoring device or any
other clinical methods for monitoring CN. None of the studies
reported on participant acceptability of the monitoring
techniques used.
3.3.4 | The influence of monitoring techniques on
the outcomes of CN
Treatments and the definitions used to confirm remission and relapse
varied between the studies. Time to healing ranged from 8 weeks to
over 1 year (Table 4). Relapse rates ranged from 0% to 35% across the
studies. The monitoring techniques were poorly reported and incon-
sistently applied across studies. Four studies did not report which
techniques were used to monitor CN.
4 | DISCUSSION
The previous systematic review on assessment, diagnosis and man-
agement in CN only included papers between 2002 and 2012,2 our
review searched from 1993 to 2018 and include an additional seven
studies7,10,14,22,28,31,38 some of which are key reference papers for
future studies.
To our knowledge, this systematic review is the first to synthesize
the evidence base for monitoring techniques of CN and influences of
different techniques for monitoring CN on treatment outcomes. We
identified a heterogeneous set of 29 papers: seven specifically evalu-
ated monitoring techniques and a further 22 described the outcomes
of CN. It is not possible to conclude whether the monitoring tech-
niques used influences the outcomes of CN. We found no high-quality
studies validating the use of monitoring techniques in CN.
The key finding is the lack of a consistent approach to monitoring
in CN. Common techniques included X-ray, temperature monitoring
and MRI. Techniques were poorly described, and where the informa-
tion was reported there was variability in the devices used and how
the technique was applied. It is not clear whether the devices used
were validated for the temperature ranges commonly found in feet.
Some studies still rely on subjective measures of temperature differ-
ence between feet to monitor CN.7,8,15,21,26,35
The first paper included in this review which used temperature
measurement for monitoring in CN was published in 1997.38 The
authors report that the cut-off point of 4F (2.2C) for healing was
22 of 25 GOODAY ET AL.
not evidence-based but it appears to have been adopted as the stan-
dard for clinical decision making in subsequent studies and guide-
lines.2,39 This protocol has not been validated and other studies have
not specified sites, repeated measures, or acclimatization times mak-
ing evaluation of studies using this technique difficult.
We found a lack of evidence on the sensitivity, specificity, cost-
effectiveness, safety and patient acceptability for all monitoring tech-
niques. There is continued uncertainty about the relationship between
monitoring techniques and treatment outcomes.
In the absence of reliable evidence, we are unable to recommend
any changes to current national39 and international guidance2 which
are predominantly based on level IV evidence, that is, expert opinion.
The strengths of our systematic review include the broad range
of inclusion and exclusion criteria for study type, which allowed us to
describe the variability in the current approach to monitoring CN in
research as well as clinical practice. Screening and data extraction
were completed by two researchers who are experienced podiatrists.
Our review also had some limitations: we did not search the grey liter-
ature. We limited searches to English language, we acknowledge that
this may mean we missed some relevant studies and potentially intro-
duced bias into the review. However, we feel that the impact of this
would be relatively small.
In the 1990s, it was acknowledged that using subtle changes in
skin temperature to inform clinical decisions may not be an accurate
way to monitor CN20 but this is still widely used in clinical practice.
Further high quality research is needed to identify the optimal method
of monitoring CN. We recommend that researchers accurately
describe the population at baseline, standardize definitions for diagno-
sis and outcome measures, and provide detailed protocols for moni-
toring techniques in future research.
MRI as a monitoring tool for CN is increasingly acknowledged as
a potentially more accurate method for monitoring and this is
supported by the studies we included.11,21,24 This warrants further
investigation. An ongoing randomized feasibility study aims to explore
the feasibility of using serial MRI without contrast in the monitoring
of CN to decide whether a large-scale trial is warranted https://doi.
org/10.1186/ISRCTN74101606.40
5 | CONCLUSION
Multiple techniques have been used to evaluate remission in acute CN,
but the quality of published studies to support any one technique is low
or very low. Uncertainty therefore remains about the effectiveness of
the different monitoring techniques, and whether the different monitor-
ing techniques influence time to remission and recurrence rates. There-
fore, we are unable to make recommendations for clinical practice.
There is an urgent need for high-quality studies to identify the most
accurate, safe and cost-effective monitoring techniques in CN.
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APPENDIX A: SEARCH STRING PUBMED
Query Items found
Search ((((((charcot joint[MeSH Terms]) OR charcot)) OR neuroarthropathy) OR osteoarthropathy)) AND ((diabetes) OR diabetes
[MeSH Terms]) Filters: Publication date from 1993/01/01 to 2018/07/24; Humans; English
784
Search ((((((charcot joint[MeSH Terms]) OR charcot)) OR neuroarthropathy) OR osteoarthropathy)) AND ((diabetes) OR diabetes
[MeSH Terms]) Filters: Humans; English
952
Search ((((((charcot joint[MeSH Terms]) OR charcot)) OR neuroarthropathy) OR osteoarthropathy)) AND ((diabetes) OR diabetes
[MeSH Terms]) Filters: Humans
1204
Search ((((((charcot joint[MeSH Terms]) OR charcot)) OR neuroarthropathy) OR osteoarthropathy)) AND ((diabetes) OR diabetes
[MeSH Terms])
1345
Search ((((charcot joint[MeSH Terms]) OR charcot)) OR neuroarthropathy) OR osteoarthropathy 11 189
Search osteoarthropathy 3292
Search neuroarthropathy 465
Search (charcot joint[MeSH Terms]) OR charcot 8067
Search (diabetes) OR diabetes[MeSH Terms] 633 535
Search charcot joint[MeSH Terms] 1604
Search charcot 7192
Search diabetes[MeSH Terms] 392 176
Search diabetes 633 535
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